Home Cart Sign in  
Chemical Structure| 1401436-95-0 Chemical Structure| 1401436-95-0

Structure of Zandelisib
CAS No.: 1401436-95-0

Chemical Structure| 1401436-95-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Zandelisib is a potent and selective inhibitor of phosphatidylinositol 3-kinase (PI3K) with IC50 of 3.5 nM for p110δ.

Synonyms: ME-401; PWT-143; ZANDELISIB [JAN]

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Zandelisib

CAS No. :1401436-95-0
Formula : C31H38F2N8O
M.W : 576.68
SMILES Code : CN1CCC(C2=CC=CC=C2CC(NC3=NC(N4C5=CC=CC=C5N=C4C(F)F)=NC(N6CCOCC6)=N3)(C)C)CC1
Synonyms :
ME-401; PWT-143; ZANDELISIB [JAN]
MDL No. :MFCD32710288

Safety of Zandelisib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H312-H315-H319-H332-H335
Precautionary Statements:P261-P264-P270-P271-P280-P301+P312-P302+P352-P304+P340-P305+P351+P338-P330-P332+P313-P337+P313-P362-P403+P233-P405-P501

Related Pathways of Zandelisib

PI3K-AKT

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02521389 Malignancies PHASE1 COMPLETED 2017-02-24 Quotient Clinical, Ruddington,... More >> Nottingham, NG11 6JS, United Kingdom Less <<
NCT04533581 Indolent B-cell Non-Hodgkin's ... More >>Lymphoma Less << PHASE2 ACTIVE_NOT_RECRUITING 2028-05-31 Anjo Kosei Hospital, Anjo, Aic... More >>hi, Japan|Aichi Cancer Center Hospital, Nagoya, Aichi, Japan|Japanese Red Cross Nagoya Daini Hospital, Nagoya, Aichi, Japan|National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan|Kameda Medical Center, Kamogawa, Chiba, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan|Gunma University Hospital, Maebashi, Gunma, Japan|Chugoku Central Hospital, Fukuyama, Hiroshima, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, Japan|Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan|Mie University Hospital, Tsu, Mie, Japan|Tohoku University Hospital, Sendai, Miyagi, Japan|Kurashiki Central Hospital, Kurashiki, Okayama, Japan|Kindai University Hospital, Osakasayama, Osaka, Japan|Osaka University Hospital, Suita, Osaka, Japan|Saitama Medical University International Medical Center, Hidaka, Saitama, Japan|Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, Japan|The Cancer Institute Hospital Of JFCR, Koto-ku, Tokyo, Japan|Tottori University Hospital, Yonago, Tottori, Japan|Akita University Hospital, Akita, Japan|Aomori Prefectural Central Hospital, Aomori, Japan|Chiba Cancer Center, Chiba, Japan|Kyushu University Hospital, Fukuoka, Japan|National Hospital Organization Kyushu Medical Center, Fukuoka, Japan|Kagoshima University Hospital, Kagoshima, Japan|National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan|Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan|Okayama University Hospital, Okayama, Japan Less <<
NCT03985189 Relapsed or Refractory Indolen... More >>t B-cell Non-Hodgkin's Lymphoma Less << PHASE1 ACTIVE_NOT_RECRUITING 2028-05-31 National Hospital Organization... More >> Nagoya Medical Center, Nagoya, Aichi, 460-0001, Japan|Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Aichi, 466-8650, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-0814, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyo-ku, Tokyo, 113-8677, Japan|National Cancer Center Hospital, Chuo-ku, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, 135-8550, Japan|Aomori Prefectural Central Hospital, Aomori, 030-8553, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|Okayama University Hospital, Okayama, 700-8558, Japan Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.73mL

0.35mL

0.17mL

8.67mL

1.73mL

0.87mL

17.34mL

3.47mL

1.73mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories